Freelance Science Writer & Journalist
RJ is a freelance science writer based in Glasgow. He covers biological and biomedical science, with a focus on the complexities and curiosities of the brain and emerging AI technologies. RJ was a science writer at Technology Networks for six years, where he also worked on the site’s SEO and editorial AI strategies. He created the site’s podcast, Opinionated Science, in 2020. RJ has a Master’s degree in Clinical Neurosciences from the University of Cambridge.
Got a Question for RJ Mackenzie?
Get in touch using the contact form linked here and we’ll get back to you shortly
Published Content
Total: 613
Industry Insight
Deploying Cloud Technologies to Fight Pediatric Cancer
The St. Jude Cloud is a recently-launched online data-sharing and collaboration platform that provides access to the largest public repository of pediatric cancer genomics data. We caught up with Jinghui Zhang, PhD, from St. Jude Children’s Research Hospital to discuss the cloud and its impact on pediatric research.
Industry Insight
A New Generation of Flow Cytometers Advances Multiomics
Flow cytometry allows the analysis of physical and biochemical features of cells. Advances in machine that can characterize and sort cells will allow researchers to look deeper than ever before into the proteome and transcriptome. We talk with Bob Balderas, VP Market Development at BD on how the cutting-edge machines like the FACSymphony S6 cell sorter incorporate new technology and advance multiomics research.
Article
"Uber for Academics" Announces a Blockchain Token for Science
Blockchain payment systems are in vogue right now, finding applications in everything from stock market transactions to air fares. Peerwith, an online peer-to-peer marketplace has announced a new blockchain currency with a grand aim: to solve the problem of payment transfers in academia.
News
CRISPR Diagnostics Could Detect Any Disease on a Paper Strip
A nucleic acid-detecting diagnostics platform that harnesses the gene editing technology CRISPR was announced today by the newly-launched Mammoth Biosciences, which says the technology could change how we diagnose disease.
Industry Insight
Data-Independent Acquisition: A Superior Technique in Mass Spectrometry?
Whilst Mass Spectrometry is undoubted in its status as a central part of the proteomics toolkit, there is still debate about the way that MS data should be acquired and analyzed. Here, we talk to Florian Marty, Director Global Product Support at Biognosys AG, about why he believes that data-independent acquisition is a superior acquisition technique.
Industry Insight
How Automation Can Help Fight Disease
Research into major diseases is a time-critical field. Automation can help make research faster and more reproducible. In this blog, we discuss the advantages and challenges of incorporating automation into pathology with Coleman Stavish, Proscia Inc's Chief Technology Officer.
Article
CRISPR Technology Could Revolutionize Animal Transgenics
Despite its role in advancing genetics research, transgenic modification of animal models is an aging and costly technique. A new tool that leverages CRISPR technology may make the entire process simpler and more efficient.
Article
RNA-Seq: Basics, Applications and Protocol
RNA-seq (RNA-sequencing) is a technique that can examine the quantity and sequences of RNA in a sample using next-generation sequencing (NGS). Here, we look at why RNA-seq is useful, how the technique works, a basic protocol that is commonly used today and challenges that remain.
Infographic
The New Era of Multiomics
This infographic explores how multiomics approaches work, gives examples of multiomics in action, and shows how using multiomics can benefit your research.
Industry Insight
Next Generation Sequencing for the Masses?
Thermo Fisher Scientific’s Oncomine Dx Target Test, a cancer diagnostics panel, is set to be made available to 160 million people in the US through both Medicare and Medicaid and private insurers. We spoke with Joydeep Goswami, president of Clinical NGS and Oncology for Thermo Fisher Scientific, about the progress of NGS tests in the clinic.
Advertisement
